Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

Brain metastases commonly develop in melanoma and are associated with poor overall survival of about five to nine months. Fortunately, new therapies, including immune checkpoint inhibitors and BRAF/MEK inhibitors, have been developed. The aim of this study was to identify outcomes of different treat...

Full description

Bibliographic Details
Main Authors: John M. Rieth, Umang Swami, Sarah L. Mott, Mario Zanaty, Michael D. Henry, Aaron D. Bossler, Jeremy D. Greenlee, Yousef Zakharia, Marion Vanneste, Brooke Jennings, Mohammed M. Milhem
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
melanoma
prognosis
cancer management
clinical cancer research
metastasis
survival
Online Access:https://www.mdpi.com/2072-6694/13/7/1489

Internet

https://www.mdpi.com/2072-6694/13/7/1489

Similar Items